ARNA

Bad Day for VIVUS: Why VVUS Stock Is Tumbling

Shares of VIVUS fell sharply in Tuesday trading after the company posted a smaller quarterly loss as investors worried about the sales of its Qsymia drug. More 

Don’t Buy Orexigen on Diet Pill Hopes

Orexigen Therapeutics joins VIVUS and Arena Pharmaceuticals in an industry that's brought nothing but disappointment to investors: weight-loss drugs. More 

3 Huge Healthcare Trends Can Fatten Your Portfolio

Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities More 

A New Rice Diet Company is Set to Launch Next Month

John Aycoth, a former Washington, D.C., lobbyist, is set to launch his Rice House Healthcare Program next month. More 

GDP, VOD News Lifts Markets: Thursday’s IP Market Recap

Markets moved ahead on solid economic news, setting aside Middle East concerns for at least one session as all 3 indices rose on the day. More 

Arena, Vivus Look Good (And It Has Nothing to Do With the AMA)

The AMA has ruled to classify obesity more intensely -- as a "disease." But are ARNA and VVUS investors justified in being excited? More 

Now That Obesity Is Classified as a ‘Disease’ …

The American Medical Association's decision to classify obesity as a disease will impact physicians, patients, insurers and pharmaceutical companies. More